TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01290198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)
Description: At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
Study: NCT00750256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
Study: NCT03173365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: 1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
Study: NCT03011905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Premedication and as needed after operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EtoriCoxib
Description: Premedication and first 2 postoperative days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EtoriCoxib
Description: Premedication and first 2 postoperative days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: In brachial plexus block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: In brachial plexus block
Study: NCT01624298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused Cognitive Behavioral Therapy
Description: TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
Study: NCT01080391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally or IV on days 1, 8, 15, 22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg orally or IV on days 1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg orally on days 1-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25 mg orally on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20 mg/m², 27 mg/m² intravenously
Study: NCT02065063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
Study: NCT00114738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (R)
Description: Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (B)
Description: Bortezomib is given alone for one cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib or observation
Description: At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
Study: NCT04116541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: HDM201 120mg, Every 3 weeks, Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib, 60 mg /day, continuous, Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib, 600mg twice daily, Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg/day, continuous, Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg/day, continuous, Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg twice daily, Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: 300 mg/day,continuous, Per os
Study: NCT00507351

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 3 questionnaires that will take 20 minutes total to complete.
Study: NCT01711775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Single oral dose Day 1, repeated oral dose once daily Days 5-14
Study: NCT03921359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMARTfit training
Description: For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMARTfit training
Description: For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical training
Description: For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical training
Description: For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.
Study: NCT01037036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Punctal Plug Delivery System
Description: To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalatan
Description: Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
Study: NCT03535532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral laparoscopic adrenalectomy
Description: unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical treatment
Description: standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
Study: NCT03330366

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allium hookeri extract
Description: take two capsules per day (486 mg/day) for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take two capsules per day
Study: NCT02338466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rt-PA
Description: 0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: 0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenecteplase
Description: Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg).
Study: NCT02003989

Intervention type: OTHER
Intervention: ophthalmologic examination and MRI
Description: thorough investigation of patients, not included in usual care.

Intervention type: OTHER
Intervention: ophthalmologic examination and MRI
Description: thorough investigation of patients, not included in usual care.
Study: NCT03689101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsies
Description: Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
Study: NCT03677934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant filled with 100 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Injections of 10 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.
Study: NCT04583358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMT-101 (oral)
Description: AMT 101 is orally administered biological therapeutic taken once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (oral)
Description: Orally administered placebo comparator taken once daily
Study: NCT00718068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Potassium Chloride Concentrate
Description: Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Potassium Chloride Concentrate
Description: By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
Study: NCT04328415

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cerebral scintigraphy
Description: Radioactive tracer 99mTc-DTPA

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cerebral scintigraphy
Description: Radioactive tracer 99mTc-DTPA
Study: NCT02567864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Beat Accupunch exercise program
Description: HBA has three phases and takes 40 minutes to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: participants maintain their daily activities.
Study: NCT00003178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT01173640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol (single dose)
Description: 1 g oral dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol (multiple dose)
Description: 1 g oral dose for 8 days
Study: NCT03276663

Intervention type: OTHER
Group type: OTHER
Intervention: Formula feeding regimen
Description: The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
Study: NCT03621982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-301
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-301
Description: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous infusion
Study: NCT01157143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRP0038 (NV1FGF)
Description: Pharmaceutical form : solution~Route of administration : intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRP0038 (NV1FGF)
Description: Pharmaceutical form : solution~Route of administration : intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRP0038 (NV1FGF)
Description: Pharmaceutical form : solution~Route of administration : intramuscular
Study: NCT02963051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper
Description: 1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper
Description: 1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper
Description: 1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: 80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: 80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: 80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Description: 1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Description: 1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Description: 1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals
Study: NCT01342887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative studies
Study: NCT03722719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Knack
Description: The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Knack + PFMT
Description: These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
Study: NCT02221323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO
Study: NCT03434613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 5mg 1T daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/ezetimibe combination
Description: Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
Study: NCT02450019

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional to protective ventilation
Description: Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protective to traditional ventilation
Description: Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
Study: NCT00663962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
Study: NCT03183557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid, Reclast®
Description: To examine the efficacy of zoledronic acid in osteoporosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®
Description: To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
Study: NCT02754414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis platelet collection
Description: A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refrigerated storage of apheresis platelets in PAS/plasma
Description: The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Infusion of aliquot of autologous radiolabeled platelets
Description: Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vitro tests
Description: Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
Study: NCT03119337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text-based follow-up
Description: 2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
Study: NCT02922985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetominophen
Description: One dose if 1 gram intravenous to be given pre-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac, intramuscular
Description: One dose of 60 mg Intramuscular to be given at time of skin closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, subcutaneous
Description: Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
Study: NCT02121743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: strattice
Description: use of a strattice

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No strattice
Description: no use of a strattice
Study: NCT03813732

Intervention type: PROCEDURE
Group type: OTHER
Intervention: orbital fracture
Description: using the trans-conjunctival approach alone in restoring the esthetics compared with using it along in addition to lateral canthotomy which is important in providing wider surgical area